<DOC>
	<DOCNO>NCT01134952</DOCNO>
	<brief_summary>Different immunosuppressive drug use transplantation may reduce body 's defence infection differently . It known patient Hepatitis C virus , know HCV , switch azathioprine mycophenolate mofetil experience increase viral load . Despite , mycophenolate mofetil use prevents rejection reliably azathioprine . Sirolimus another immunosuppressive agent reliably prevent rejection may antiviral activity . This study design see viral load HCV viruses reduce switch mycophenolate sirolimus .</brief_summary>
	<brief_title>Study Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) persistence liver transplantation HCV end-stage liver disease universal clinical setting , HCV mediate liver injury report follow progressive course compare non-immunosuppressed patient . Additionally , patient recurrent chronic hepatitis C develop high viral load compare pre-transplant level . Such persistently high viral burden post transplant may contribute allograft damage . The choice calcineurin inhibitor ( CNI ) effect recurrence rate HCV hepatitis . HCV also associate renal dysfunction reduction exposure calcineurin inhibitor ( CNI ) desirable . Unfortunately steroid associate marked increase HCV replication use reduce CNI dos . Mycophenolate mofetil ( MMF ) increase HCV viral load . A recent increase severity recurrent hepatitis patient HCV receive liver transplant attribute MMF interleukin-2 receptor blocker . Increased fibrosis liver occur antiviral anti HCV treatment patient take mycophenolate patient azathioprine develop cirrhosis faster , possibly rejection . A large industry sponsor phase III clinical trial underway several year patient substitute sirolimus ( SRL ) calcineurin inhibitor liver transplantation . The object study determine impact conversion renal function . No detrimental effect ( thrombosis , rejection recurrent viral infection ) apparent safety board two review . No study compare SRL MMF liver transplantation . SRL , immunosuppressive drug inhibits activation proliferation T-lymphocytes , associate reduction Epstein Barr Virus ( EBV ) post-transplantation viral load child . Experimentally inhibit growth EBV B-cell lymphoma . A pilot study tacrolimus SRL show powerful anti-rejection effect subsequent trial halt early increase hepatic artery thrombosis even though rate thrombosis either arm study expect . A recent large series patient hepatocellular carcinoma ( HCV ) receive large dos SRL show beneficial anti-cancer effect without thrombosis . The randomised trial report series large number patient HCV . The absence obvious recurrent HCV hepatitis low rate cytomegalovirus ( CMV ) disease couple know inhibition EBV replication give hope SRL anti-viral property immunosuppressive dos . Early report confirm hope : 1 ) successful liver transplantation patient HIV HCV . `` Significantly good control HIV HCV replication find among patient take RAPA monotherapy ( P=0.0001 0.03 , respectively ) '' ; 2 ) switch sirolimus renal transplant recipient hepatitis C virus : HCV replication reduce switch sirolimus ; 3 ) sustain , spontaneous disappearance serum HCV-RNA immunosuppression liver transplantation HCV cirrhosis : two liver recipient spontaneously clear HCV switch sirolimus . SRL ( 2 mg/day ) MMF ( 2g/day ) license adjuvant immunosuppressive agent use kidney transplantation cyclosporine immunosuppressive equivalent dos 1mg SRL = 1g MMF .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Recurrent HCV liver transplantation Taking mycophenolate mofetil Stable liver function Pregnant females couple unwilling use contraception Intolerance allergy sirolimus Patients take antiHCV therapy Patients take medication know alter level sirolimus History thromboembolic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>sirolimus</keyword>
	<keyword>everolimus</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>viral load</keyword>
</DOC>